According to ACOG’s CO 773 from 2019, “Currently, serum antimüllerian hormone levels are not part of the accepted diagnostic criteria for polycystic ovary syndrome (PCOS)”. But medicine moves fast, and that statement is no longer valid, at least it isn’t valid from the ASRM July 2023 Standpoint. Yep, once considered experimental, AMH has now entered the PCOS diagnostic algorithm. Nonetheless, some important limitations and facts must be understood for its use in this way. In this episode, we will highlight the recommendations from the 2023 international, evidence-based guideline for the assessment and management of polycystic ovary syndrome, focusing on the role of AMH. We will also discuss the condition in adolescents and why this diagnosis is DIFFERENT in this group, and the update to the number of follicles per ovary (FNPO) recommended for the diagnosis. This guideline has been co-published in Fertility and Sterility, Human Reproduction, European Journal of Endocrinology, and The Journal of Clinical Endocrinology and Metabolism.
